Strides Pharma Science Ltd Stock Analysis

BSE: 532531 | NSE: STAR | Pharmaceuticals & Drugs | Small Cap

BSE Share Price Jan 24, 11:59
389.00 -12.00 (-2.99%)

DeciZen - Make an Informed Decision on Strides Pharma Scien

Overall Rating

1. Quality

2. Valuation

Somewhat Undervalued

3. Price Trend


1. Is Strides Pharma Science Ltd a good quality company?

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Strides Pharma Science Ltd is a below average quality company.

2. Is Strides Pharma Science Ltd undervalued or overvalued?

The key valuation ratios of Strides Pharma Science Ltd's currently when compared to its past seem to suggest it is in the Somewhat Undervalued zone.

3. Is Strides Pharma Science Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Strides Pharma Science Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Strides Pharma Scien:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Strides Pharma Science Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good

Value Creation

Value Creation Index Colour Code Guide
ROCE % 5.6%8.5%21.7%9.2%6.6%2.1%21.9%4%4.4%2.5%-
Value Creation Index -0.6-0.40.6-0.3-0.5-0.90.6-0.7-0.7-0.8-

Growth Parameters

Growth Parameters Colour Code Guide
Sales 7507128519292,2221,3821,9551,5371,6921,8582,138
YoY Gr. Rt. %--5%19.5%9.2%139%-37.8%41.5%-21.4%10.1%9.8%-
Adj EPS 13.922.449.926.716.15.498.713.
YoY Gr. Rt. %-61.1%122.5%-46.5%-39.7%-66.7%1741.8%-86.6%9.1%-57%-
BVPS (₹) 232.4232.6219247.2352.8360.5352.3362.8352361.7359.7
Adj Net Profit 81.213229715914447.988411912955.866
Cash Flow from Ops. 10211.1-2.720783.141265.640138283-
Debt/CF from Ops. 8.857-141.3218.


CAGR Colour Code Guide
9 Years 5 Years 3 Years 1 Years
Sales 10.6%-3.5%-1.7%9.8%
Adj EPS -8.6%-17.3%-60.2%-57%
Share Price -2% -19.2% -9.9% -54.1%

Key Financial Parameters

Performance Ratio Colour Code Guide
Return on Equity % 5.99.724.710.26.21.527.63.741.72
Op. Profit Mgn % 20.319.61714.412.
Net Profit Mgn % 10.818.534.917.16.53.545.27.77.733.1
Debt to Equity
Working Cap Days 933726464783293405295383333340301
Cash Conv. Cycle 3979759157123399310713235

Recent Performance Summary

Sales growth is good in last 4 quarters at 30.91%

Return on Equity has declined versus last 3 years average to 2.00%

Sales growth has been subdued in last 3 years -1.70%

Latest Financials - Strides Pharma Science Ltd.

Standalone Consolidated
TTM EPS (₹) 7.3 -31.6
TTM Sales (₹ Cr.) 2,138 3,150
BVPS (₹.) 359.7 267.9
Reserves (₹ Cr.) 3,139 2,316
P/BV 1.12 1.50
PE 54.67 0.00
From the Market
52 Week Low / High (₹) 403.55 / 946.80
All Time Low / High (₹) 60.65 / 1412.45
Market Cap (₹ Cr.) 3,600
Equity (₹ Cr.) 89.8
Face Value (₹) 10
Industry PE 39.1

Management X-Ray of Strides Pharma Scien :

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *51.2948.2050.9346.8437.0440.3832.5626.0226.0237.84
* Pledged shares as % of Promoter's holding (%)

Event Update

Analyst's Notes


About Strides Pharma Science Ltd

Strides Pharma Science Limited, incorporated in 1990, is a global pharmaceutical company headquartered in Bangalore, India. The Company has two business verticals, viz., Regulated Markets and Emerging Markets. Strides has a global manufacturing footprint with eight manufacturing facilities spread across four continents, including five US FDA approved facilities and two facilities for the rest of world markets. The Company has a dedicated R&D facility in India with global filing capabilities and a strong footprint across many countries.

Business area of the company

The company’s core competence is in the development and manufacture of wide range of niche and technically complex pharmaceutical products. The company is also among the world's largest soft gelatin capsule manufacturers.


Soft gel capsules - The company manufactures range of soft gel in category of nutraceuticals, Rx, specialty OTCs and immunosuppressants.

Steriles- Under this, it offers its products in therapeutic segments that includes beta-lactams and cephalosporins. The company manufactures striles in various forms such as prefill syringes, ampoules, vials and penicillins.



  • Received several customer award including the Cardinal Health Supply Chain Excellence Award for 2017


  • The Global Presence Award
  • Foreign owned business Award



  • Strides Arcolab receives ANDA approval from USFDA for Tenofovir Disoproxil Fumarate and Emtricitabine Tablet.
  • Strides Arcolab announces US FDA approval for its Italian Semi-solids and Oinment facility.
  • Strides announces WHO pre-qualification for Artemether + Lumifantrine -StelisBiopharma and Pieris Forge Alliance for Novel Anticalin Therapeutics in Ophthalmology.
  • Strides Arcolab - Re-branding Biotech Business as ''Stelis''.
  • Strides Arcolab - Pfenex Inc. and Agila Biotech Private Ltd Announce Joint Venture to Develop Biosimilar Products for the Global Market.


  • Medicines for Malaria Venture announces collaborations with Cipla and Strides.
  • Strides Arcolab makes strategic investment in Oncobiologics Inc., USA.
  • Strides partners with Gilead Sciences Inc, to bring Hepatitis C cure to 91 developing countries.
  • Strides Arcolab receives US FDA approval for Buspirone Tablets.
  • Strides Arcolab receives US FDA approval for Calcitriol Softgel.
  • Strides Arcolab acquires 'Raricap' and India Branded Generic Business of Bafna.
  • Strides Arcolab to acquire Shasun Pharma in all stock deal.


  • Strides Arcolab Ltd. has entered into an agreement with Fortuna Public Relations Pvt. Ltd., Delhi appointing them as Company's Public Relations Agenc
  • Strides Arcolab Ltd that it has entered into a licensing agreement with Gilead Sciences Inc,
  • Strides Arcolab Ltd has launched the generic drug Sofosbuvir in India ''Virso''
  • Strides Arcolab gets USFDA nod for Polyethylene Glycol 3350 -Strides Arcolab gets USFDA nod for HIV treatment drug
  • Strides Arcolab Ltd has approved the merger of Shasun Pharmaceuticals Ltd with the company.
  • Strides Arcolab has completed the Rs 1,910-crore acquisition of Aspen Pharmacare, Australia.
  • Strides Arcolab acquires CNS divisions of erstwhile Ranbaxy
  • Strides Arcolab Ltd has changed from its present name ''Strides Arcolab Limited'' to Strides Shasun Limited


  • Strides Shasun updates on ''Acquisition of seven brands from Johnson & Johnson''.
  • Strides Shasun update on ''Acquisition of CNS divisions of erstwhile Ranbaxy''. -''Strides Shasun to acquire a strategic stake in Generic Partners Holdings, Australia.
  • Strides Shasun to acquire controlling stake in Universal Corporation, Kenya.
  • Strides Shasun receives USFDA Tentative Approval for Efavirenz Tablet.
  • Strides Shasun announces successful completion of US FDA inspection at its Oral Dosage Facility in Bangalore.


  • Launched consumer health division in a difficult market environment.
  • Product filing and approval gained momentum with 12 new ANDA filings and 14 product approvals received
  • Witnessed single-digit price erosion for front-end portfolio 


  • Re-launched erstwhile partnership molecules through front-end business witnessing encouraging traction which contributed to a sequential ramp-up in the US business.
  • Completed acquisition of Vensun Pharmaceuticals and took 100% ownership in a joint venture with Vivimed Labs adding ~US$ 25 million additional sales and a combined portfolio of 100+ ANDAs.
  • Entered into a strategic partnership with SUDA Pharmaceuticals for an exclusive agreement for novel and a fast-acting oral spray of sumatriptan in the US market.


  • Increased production capacity up to 1.4 Billion tablets annually on single shift operations, with new equipment-like continuous coater, high speed automatic inspection machine-and technology - for manufacturing hot molten liquid fill into a hard gelatin capsule
  • Successfully transferred eight products of which three are approved by the US FDA; the remaining five products are expected to receive US FDA approval within the next six months.
  • Implemented Manufacturing Execution System (MES) in processing facility, with integrated electronic batch record.
  • Installed packaging serialization and automated materials tracking system (GEM-MT).
  • Equipped the unit with laser-based, high-end inspection system for scanning tablets and capsules with 3D cameras, which can identify defects as low as 20 microns leading to a high level of automated quality controls.
  • Launched two products from the Singapore unit under the procurements administered by the Department of Veteran Affairs (VA) in the US, based on its eligibility as a designated country.
  • Initiated transfer of eight new products to be manufactured in the Singapore unit.
Read More Read Less